MarketPulse

DCCR drug candidate

8 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Faces Securities Class Action Over Undisclosed Drug Safety Concerns

Investors in $SLNO have until May 5, 2026 to join securities lawsuit alleging undisclosed safety issues with DCCR drug candidate.
SLNOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Bragar Eagel & Squire, P.C.

Class Action Targets Soleno Therapeutics Over DCCR Safety Disclosure Gap

Soleno Therapeutics faces class action lawsuit alleging false safety disclosures about DCCR drug candidate for Prader-Willi syndrome.
SLNOclass action lawsuitinvestor losses
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed Drug Safety Issues

Rosen Law Firm alerts $SLNO investors of May 5, 2026 deadline in securities class action alleging false statements about DCCR drug candidate safety risks.
SLNOsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over DCCR Safety Disclosures

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors have until May 5, 2026 deadline to join lawsuit.
SLNOsecurities class actionlead plaintiff deadline
BenzingaBenzinga··The Law Offices Of Frank R. Cruz

SLNO Shareholders Sue Over Alleged Safety Disclosure Failures in PWS Drug Trial

Soleno Therapeutics faces securities fraud lawsuit alleging failure to disclose safety concerns about DCCR drug candidate between March 2025 and November 2026.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Soleno Therapeutics Faces Securities Lawsuit Over Undisclosed Safety Risks in DCCR Trial

Rosen Law Firm files class action against Soleno Therapeutics for allegedly concealing fluid retention safety concerns in DCCR clinical trials, affecting drug viability.
SLNOsecurities fraudclass action lawsuit
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Soleno Therapeutics Faces Securities Lawsuit Over DCCR Safety Disclosures

Securities class action filed against $SLNO alleging false statements about DCCR drug safety. Investors must claim lead plaintiff status by May 5, 2026.
SLNOstock declinesecurities class action
GlobeNewswire Inc.GlobeNewswire Inc.··Faruqi & Faruqi, Llp

Soleno Therapeutics Faces Securities Fraud Probe Over Undisclosed Safety Data

Law firm probing Soleno Therapeutics for allegedly concealing safety data on drug DCCR. Investors must file claims by May 5, 2026.
SLNOstock declinesecurities class action